Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Blood (2024) 143 (23): 2401–2413.

https://doi.org/10.1182/blood.2023022540

Published: 2024

Includes: Supplemental data

Journal Articles

Whole Exome Sequencing Analysis of Diffuse Large B-Cell Lymphoma That Progressed to Central Nervous System

Tomotaka Suzuki, Rui Yokomori, Takaomi Sanda, Hiroki Yano, Takaki Kikuchi, Takashi Kanamori, Atsushi Inagaki, Takashi Yoshida, Satoshi Kayukawa, Yoshiko Oshima, Hirokazu Sasaki, Shiori Kinoshita, Tomoko Narita, Ayako Masaki, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Hiroshi Inagaki, Shinsuke Iida

Blood (2023) 142 (Supplement 1): 1632.

https://doi.org/10.1182/blood-2023-174341

Published: 2023

Journal Articles

Thrombocytopenia and Low CD4/CD8 Ratio at Apheresis Along with Prior Bendamustine Use Increase Risk of CAR-T Cell Manufacturing Failure

Tomoyasu Jo, Yasuyuki Arai, Satoshi Yoshihara, Minoru Kojima, Junko Ikemoto, Tomoe Uemura, Keita Iwaki, Noboru Yonetani, Shin-ichiro Fujiwara, Masaki Ri, Kaoru Kahata, Tokiko Nagamura-Inoue, Minami Yamada-Fujiwara, Ryuji Tanosaki

Blood (2022) 140 (Supplement 1): 1608–1609.

https://doi.org/10.1182/blood-2022-165613

Published: 2022

Journal Articles

Circulating miRNA Profiling of Plasma Samples from Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study to Predict the Response and Toxicity of Bortezomib-Containing Regimen: An Ancillary Study of JCOG1105 (JCOG1105A1)

Masaki Ri, Shimon Nakashima, Miki Nakajima, Shinsuke Iida, Dai Maruyama, Satoshi Osaga, Kensei Tobinai, Noriko Fukuhara, Kana Miyazaki, Norifumi Tsukamoto, Hideki Tsujimura, Makoto Yoshimitsu, Kenichi Miyamoto, Kunihiro Tsukasaki, Hirokazu Nagai

Blood (2022) 140 (Supplement 1): 12647–12649.

https://doi.org/10.1182/blood-2022-156875

Published: 2022

Journal Articles

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Takahiko Murayama, PhD, Kota Sato, MD PhD, Junichi Yamamoto, PhD, Takumi Ito, PhD, Muneyoshi Futami, MD PhD, Masaki Ri, Hiroshi Yasui, MD PhD, Noriko Gotoh, MD, Shinsuke Iida, MD PhD, Tadao Ishida, MD PhD, Hiroshi Handa, MD PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 4325.

https://doi.org/10.1182/blood-2019-122662

Published: 2019

Journal Articles

Lipidomic Profiling of Plasma Samples in Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study for Predicting the Response and Toxicities of Melphalan, Prednisolone and Bortezomib (MPB) Regimen : An Ancillary Study of the JCOG1105 (JCOG1105A1)

Masaki Ri, Shinsuke Iida, MD PhD, Dai Maruyama, MD PhD, Kosuke Saito, Yoshiro Saito, Satoshi Osaga, Masahiro Tohkin, Naoki Miyata, Kensei Tobinai, MD PhD, Noriko Fukuhara, MD PhD, Kana Miyazaki, MD PhD, Yosuke Minami, MD PhD, Norifumi Tsukamoto, MD PhD, Hideki Tsujimura, MD PhD, Makoto Yoshimitsu, MD PhD, Kenichi Miyamoto, Kunihiro Tsukasaki, MD PhD, Hirokazu Nagai, MD PhD

Blood (2019) 134 (Supplement_1): 3156.

https://doi.org/10.1182/blood-2019-122218

Published: 2019

Journal Articles

Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma

Blood (2017) 130 (9): 1114–1124.

https://doi.org/10.1182/blood-2016-09-741983

Published: 2017

Includes: Supplemental data

Journal Articles

Aberrantly Expressed APOBEC3B Induces Mutations in Multiple Myeloma

Hiroyuki Yamazaki, MD, Kotaro Shirakawa, MD PhD, Tadahiko Matsumoto, MD, Hiroyuki Matsui, MD, Wataru Maruyama, MD, Masayuki Kobayashi, MD PhD, Keisuke Shindo, MD PhD, Anamaria Daniela Sarca, MD, Masaki Ri, MD PhD, Shinsuke Iida, MD PhD, Akifumi Takaori-Kondo, MD PhD

Blood (2016) 128 (22): 4453.

https://doi.org/10.1182/blood.V128.22.4453.4453

Published: 2016

Journal Articles

The Abnormal Repression of Mir-375 Expression By Overlapping Epigenetic Dysregulations in Myelomas

Shotaro Tatekawa, MD, Yoshiaki Chinen, MD PhD, Yuji Shimura, MD PhD, Yayoi Matsumura-Kimoto, MD, Hisao Nagoshi, MD PhD, Tsutomu Kobayashi, MD PhD, Eri Kawata, MD PhD, Tomoko Narita, MD PhD, Masaki Ri, MD PhD, Hiroshi Handa, MD PhD, Nobuhiko Uoshima, MD PhD, Shinsuke Iida, MD PhD, Junya Kuroda, MD PhD

Blood (2016) 128 (22): 4460.

https://doi.org/10.1182/blood.V128.22.4460.4460

Published: 2016

Journal Articles

Anti-Myeloma Activity of a Syringolin Analog: A Dual 20S Proteasome Inhibitor of Beta 2 and 5 Subunits

Takashi Yoshida, MD, Masaki Ri, MD PhD, Shiori Kinoshita, MD, Tomoko Narita, MD PhD, Haruhito Totani, MD, Reham Ashour, MD, Ayako Masaki, MD PhD, Asahi Ito, MD PhD, Shigeru Kusumoto, MD PhD, Takashi Ishida, MD PhD, Hirokazu Komatsu, MD PhD, Satoshi Ichikawa, Ph, PhD, Shinsuke Iida, MD PhD

Blood (2016) 128 (22): 4473.

https://doi.org/10.1182/blood.V128.22.4473.4473

Published: 2016

Journal Articles

Identification of Circulating Serum microRNAs As Novel Biomarkers Predicting Disease Progression and Sensitivity to Bortezomib Treatment in Multiple Myeloma

Tomoko Narita, MD PhD, Masaki Ri, MD PhD, Shiori Kinoshita, MD, Takashi Yoshida, MD, Haruhito Totani, MD, Reham Ashour, MD, Ayako Masaki, MD PhD, Asahi Ito, MD PhD, Shigeru Kusumoto, MD PhD, Takashi Ishida, MD PhD, Hirokazu Komatsu, MD PhD, Makoto Osabe, PhD, Masahiro Tohkin, PhD, Shinsuke Iida, MD PhD

Blood (2016) 128 (22): 4408.

https://doi.org/10.1182/blood.V128.22.4408.4408

Published: 2016

Journal Articles

3-Phosphoinositide-Dependent Protein Kinase 1 (PDPK1) Is a Pivotal Cell Signaling Mediator in Multiple Myeloma

Yoshiaki Chinen, MD, Junya Kuroda, MD PhD, Yuji Shimura, MD PhD, Hisao Nagoshi, MD PhD, Miki Kiyota, MD PhD, Mio Yamamoto-Sugitani, MD PhD, Shinsuke Mizutani, MD, Natsumi Sakamoto, Masaki Ri, MD PhD, Eri Kawata, MD PhD, Tsutomu Kobayashi, MD PhD, Yosuke Matsumoto, MD PhD, Shigeo Horiike, MD PhD, Shinsuke Iida, Masafumi Taniwaki, MD PhD

Blood (2014) 124 (21): 4728.

https://doi.org/10.1182/blood.V124.21.4728.4728

Published: 2014

Journal Articles

Chromosomal Translocation (14;16)-Positive Multiple Myeloma Shows Negativity for CD56 Expression and Unfavorable Outcome Even in the Era of Novel Drugs

Blood (2014) 124 (21): 3349.

https://doi.org/10.1182/blood.V124.21.3349.3349

Published: 2014

Journal Articles

Amylase-Producing Myeloma Cells Reduced Sensitivity to Dexamethasone and Bortezomib.

Shohei Mizuno, MD, Ichiro Hanamura, MD PhD, Akinobu Ota, Karnan Sivasundaram, Tomoko Narita, MD, Masaki Ri, MD PhD, Motonori Mizutani, MD, Mineaki Goto, MD PhD, Mayuko Gotou, MD PhD, Norikazu Tsunekawa, MD PhD, Masato Shikami, MD PhD, Shinsuke Iida, Yoshitaka Hosokawa, MD PhD, Hiroshi Miwa, MD PhD, Ryuzo Ueda, MD PhD, Masakazu Nitta, MD PhD, Akiyoshi Takami, MD PhD

Blood (2014) 124 (21): 5690.

https://doi.org/10.1182/blood.V124.21.5690.5690

Published: 2014

Journal Articles

TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways

Morihiko Sagawa, MD, PhD, Tatsuki Tomikawa, MD, Tomoe Anan, MD, Takayuki Tabayashi, MD, PhD, Reiko Watanabe, MD, PhD, Michihide Tokuhira, MD, PhD, Masaki Ri, MD, PhD, Yuichi Hashimoto, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2013) 122 (21): 4427.

https://doi.org/10.1182/blood.V122.21.4427.4427

Published: 2013

Journal Articles

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

Takeshi Harada, MD, Shuji Ozaki, MD, PhD, Asuka Oda, PhD, Masami Iwasa, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, PhD, Kumiko Kagawa, MD, PhD, Masahiro Abe, MD, PhD, Hironobu Shibata, MD, PhD, Akishige Ikegame, MD, PhD, Daisuke Tsuji, PhD, Kohji Itoh, PhD, Masaki Ri, MD, PhD, Shinsuke Iida, MD, PhD, Yukimasa Shiotsu, PhD, Shigeto Kawai, PhD, Hisafumi Yamada-Okabe, PhD, Toshio Matsumoto, MD, PhD

Blood (2012) 120 (21): 1839.

https://doi.org/10.1182/blood.V120.21.1839.1839

Published: 2012

Journal Articles

RSK2 Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.

Yuji Shimura, MD, Junya Kuroda, MD, PhD, Hisao Nagoshi, MD, Mio Yamamoto-Sugitani, MD, PhD, Tsutomu Kobayashi, MD, PhD, Miki Kiyota, MD, Ryuko Nakayama, MD, Shinsuke Mizutani, MD, Yoshiaki Chinen, MD, Natsumi Sakamoto, Yosuke Matsumoto, MD, PhD, Shigeo Horiike, MD, PhD, Masaki Ri, MD, PhD, Yukimasa Shiotsu, PhD, Shinsuke Iida, MD, PhD, Tomohiko Taki, MD, PhD, Masafumi Taniwaki, MD, PhD

Blood (2012) 120 (21): 2945.

https://doi.org/10.1182/blood.V120.21.2945.2945

Published: 2012

Journal Articles

A Biomarker Obtained From Whole Peripheral Blood Predicts Response to Bortezomib: Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan.

Takashi Watanabe, MD, PhD, Masato Mitsuhashi, MD, PhD, Morihiko Sagawa, MD, PhD, Kenshi Suzuki, MD, PhD, Masaki Ri, MD, PhD, Masahiro Abe, MD, PhD, Ken Ohmachi, MD, Yasunori Nakagawa, MD, PhD, Shingen Nakamura, MD, Mizuki Chosa, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2012) 120 (21): 2954.

https://doi.org/10.1182/blood.V120.21.2954.2954

Published: 2012

Journal Articles

Discovery of Unique Biomarkers That Predict Bortezomib-Induced Peripheral Neuropathy: The Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan

Blood (2012) 120 (21): 1816.

https://doi.org/10.1182/blood.V120.21.1816.1816

Published: 2012

Journal Articles

TM-233, a Novel Analog of 1'-Acetoxychavicol Acetate (ACA), Induces Cell Death in Human Myeloma Cells by Inhibiting Both JAK/STAT and NF-κB Pathways: A Possible New Agent for Overcoming Bortezomib-Resistance.

Morihiko Sagawa, MD, PhD, Tatsuki Tomikawa, MD, Tomoe Nemoto, MD, Takayuki Tabayashi, MD, PhD, Reiko Watanabe, MD, PhD, Michihide Tokuhira, MD, PhD, Masaki Ri, MD, PhD, Yuichi Hashimoto, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2012) 120 (21): 2939.

https://doi.org/10.1182/blood.V120.21.2939.2939

Published: 2012

NARROW

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Whole Exome Sequencing Analysis of Diffuse Large B-Cell Lymphoma That Progressed to Central Nervous System

Thrombocytopenia and Low CD4/CD8 Ratio at Apheresis Along with Prior Bendamustine Use Increase Risk of CAR-T Cell Manufacturing Failure

Circulating miRNA Profiling of Plasma Samples from Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study to Predict the Response and Toxicity of Bortezomib-Containing Regimen: An Ancillary Study of JCOG1105 (JCOG1105A1)

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Lipidomic Profiling of Plasma Samples in Patients with Newly Diagnosed Multiple Myeloma; A Biomarker Study for Predicting the Response and Toxicities of Melphalan, Prednisolone and Bortezomib (MPB) Regimen : An Ancillary Study of the JCOG1105 (JCOG1105A1)

Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma

Aberrantly Expressed APOBEC3B Induces Mutations in Multiple Myeloma

The Abnormal Repression of Mir-375 Expression By Overlapping Epigenetic Dysregulations in Myelomas

Anti-Myeloma Activity of a Syringolin Analog: A Dual 20S Proteasome Inhibitor of Beta 2 and 5 Subunits

Identification of Circulating Serum microRNAs As Novel Biomarkers Predicting Disease Progression and Sensitivity to Bortezomib Treatment in Multiple Myeloma

3-Phosphoinositide-Dependent Protein Kinase 1 (PDPK1) Is a Pivotal Cell Signaling Mediator in Multiple Myeloma

Chromosomal Translocation (14;16)-Positive Multiple Myeloma Shows Negativity for CD56 Expression and Unfavorable Outcome Even in the Era of Novel Drugs

Amylase-Producing Myeloma Cells Reduced Sensitivity to Dexamethasone and Bortezomib.

TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

RSK2 Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.

A Biomarker Obtained From Whole Peripheral Blood Predicts Response to Bortezomib: Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan.

Discovery of Unique Biomarkers That Predict Bortezomib-Induced Peripheral Neuropathy: The Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan

TM-233, a Novel Analog of 1'-Acetoxychavicol Acetate (ACA), Induces Cell Death in Human Myeloma Cells by Inhibiting Both JAK/STAT and NF-κB Pathways: A Possible New Agent for Overcoming Bortezomib-Resistance.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only